1. Oxford National Institute for Health Research Biomedical Research Centre/Molecular Diagnostic Centre, University of Oxford, Oxford, United Kingdom;
2. Institut de Génétique Humaine, Centre National de la Recherche Scientifique-Unités Propres de Recherche 1142, Montpellier, France;
3. Clinical Haematology, Bradford Teaching Hospitals, National Health Service Foundation Trust, Bradford, United Kingdom;
4. Laboratory of Molecular Hematology, Institut National de la Santé et de la Recherche Médicale U462, Centre Hayem, Hopital Saint Louis, Paris, France;
5. Xentech SAS, Genopole, Evry, France;
6. Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland;
7. Medical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom;
8. Athens University of Economics and Business, Athens, Greece;
9. Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;
10. Illumina Cambridge Ltd., Saffron Walden, United Kingdom;
11. St. James’ Institute of Oncology, Leeds, United Kingdom;
12. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom;
13. Oxford National Institute for Health Research Biomedical Research Centre and Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom; and
14. Genetic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, St. Mary's Hospital, Central Manchester University Hospitals National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom